KINARUS THERAPEUTICS HOLDING AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.6 CHF | -2.37% |
|
-0.59% | +263.84% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 12.75 | 0.5241 |
| Enterprise Value (EV) 1 | 14.41 | 0.5151 |
| P/E ratio | -0.23 x | -0.01 x |
| Yield | - | - |
| Capitalization / Revenue | 3.82 x | - |
| EV / Revenue | 4.32 x | - |
| EV / EBITDA | -45.3 x | -0.13 x |
| EV / FCF | - | -143,731 x |
| FCF Yield | - | -0% |
| Price to Book | 1.85 x | -1.68 x |
| Nbr of stocks (in thousands) | 250 | 292 |
| Reference price 2 | 51.07 | 1.792 |
| Announcement Date | 4/17/24 | 4/17/24 |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Net sales 1 | 3.336 | - |
| EBITDA 1 | -0.318 | -3.862 |
| EBIT 1 | -1.84 | -4.351 |
| Operating Margin | -55.16% | - |
| Earnings before Tax (EBT) 1 | -39.9 | -50.76 |
| Net income 1 | -34.73 | -49.38 |
| Net margin | -1,041.13% | - |
| EPS 2 | -221.6 | -176.4 |
| Free Cash Flow | - | -3.584 |
| FCF margin | - | - |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share | - | - |
| Announcement Date | 4/17/24 | 4/17/24 |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Net Debt 1 | 1.66 | - |
| Net Cash position 1 | - | 0.01 |
| Leverage (Debt/EBITDA) | -5.214 x | - |
| Free Cash Flow | - | -3.58 |
| ROE (net income / shareholders' equity) | - | -1,533% |
| ROA (Net income/ Total Assets) | - | -38.4% |
| Assets 1 | - | 128.6 |
| Book Value Per Share 2 | 27.50 | -1.070 |
| Cash Flow per Share 2 | 5.470 | 0.0300 |
| Capex 1 | 0 | - |
| Capex / Sales | 0.12% | - |
| Announcement Date | 4/17/24 | 4/17/24 |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- CURE Stock
- Financials Kinarus Therapeutics Holding AG
